These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Robinson A; Hankins M; Wiseman G; Jones M Aliment Pharmacol Ther; 2013 Sep; 38(5):531-8. PubMed ID: 23834298 [TBL] [Abstract][Full Text] [Related]
6. 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose. Qasim A; Seery J; O'Morain CA Dig Liver Dis; 2001; 33(5):393-8. PubMed ID: 11529648 [No Abstract] [Full Text] [Related]
7. The MMAS-8, a screening tool for determining nonadherent behavior, should not be dismissed in IBD. Trindade AJ; Tinsley A; Kornbluth A; Ullman TA Am J Gastroenterol; 2012 Jun; 107(6):951-2; author reply 952. PubMed ID: 22664851 [No Abstract] [Full Text] [Related]
8. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. Devlen J; Beusterien K; Yen L; Ahmed A; Cheifetz AS; Moss AC J Manag Care Spec Pharm; 2014 Mar; 20(3):309-14. PubMed ID: 24564811 [TBL] [Abstract][Full Text] [Related]
9. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
11. Response to the letter of Gifford and Moss. Moshkovska T; Inflamm Bowel Dis; 2013 Feb; 19(2):E19-20. PubMed ID: 22180002 [No Abstract] [Full Text] [Related]
12. Letter: wide variation in faecal calprotectin values according to the assay - authors' reply. Yamamoto T; Shimoyama T; Matsumoto K Aliment Pharmacol Ther; 2016 Jan; 43(1):178. PubMed ID: 26638942 [No Abstract] [Full Text] [Related]
13. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases]. Ioffe AIu Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715 [TBL] [Abstract][Full Text] [Related]
14. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Kane S; Becker B; Harmsen WS; Kurian A; Morisky DE; Zinsmeister AR Am J Gastroenterol; 2012 Feb; 107(2):154-60. PubMed ID: 22306937 [TBL] [Abstract][Full Text] [Related]
15. Is non-adherence to blame? Kane S Inflamm Bowel Dis; 2005 Jul; 11(7):705. PubMed ID: 15973128 [No Abstract] [Full Text] [Related]
16. [Probiotics in gastrointestinal diseases]. Braun S; Budak K; Vavricka S Praxis (Bern 1994); 2012 Aug; 101(17):1077-85. PubMed ID: 22915509 [No Abstract] [Full Text] [Related]
17. [Aminosalicylates in the treatment of idiopathic inflammatory bowel disease]. Lukás K Vnitr Lek; 1996 Feb; 42(2):117-9. PubMed ID: 8686186 [No Abstract] [Full Text] [Related]